Clinical and virological aspects of hepatitis B co-infection in individuals infected with human immunodeficiency virus type-1

被引：9

作者：

Cooley, L

Sasadeusz, J ^{[1
]}

机构：

[1] Alfred Hosp, Prahran, Vic, Australia

[2] Victorian Infect Dis Reference Lab, Melbourne, Vic, Australia

[3] Royal Melbourne Hosp, Victorian Infect Dis Serv, Parkville, Vic 3050, Australia

来源：

JOURNAL OF CLINICAL VIROLOGY | 2003年 / 26卷 / 02期

关键词：

hepatitis B; HIV; co-infection; antiretroviral therapy; HAART; hepatotoxicity;

D O I：

10.1016/S1386-6532(02)00117-8

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

The improved prognosis of HIV-infection that has occurred since the introduction of highly active antiretroviral therapy (HAART) has resulted in renewed emphasis being placed on co-morbidities associated with HIV-infection, and chronic viral hepatitis in particular. Hepatitis B virus (HBV) infection is an important infection in HIV-1 infected individuals because of the influence of HIV-1 co-infection on the natural history of HBV infection. Antiviral therapies with activity against both viruses have enabled targeted therapy in co-infected individuals, however, optimism regarding improved prognosis has been tempered by the development of antiviral resistant HBV. Emerging new classes of HBV therapies herald the possibility of combination HBV therapy. (C) 2002 Elsevier Science B.V. All rights reserved.

引用

收藏

页码：185 / 193

页数：9

相关论文

共 67 条

[1] HEPATITIS-B VIRUS-INFECTION AND VACCINATION STATUS OF HIGH-RISK PEOPLE IN SYDNEY - 1982 AND 1991 [J].

ANDERSON, B ;

BODSWORTH, NJ ;

ROHRSHEIM, RA ;

DONOVAN, BJ .

MEDICAL JOURNAL OF AUSTRALIA, 1994, 161 (06) :368-371

[2] Anti-HIV and anti-HBV activity and resistance profile of 2',3'-dideoxy-3'-thiacytidine (3TC) and its arylphosphoramidate derivative CF 1109 [J].

Balzarini, J ;

Wedgwood, O ;

Kruining, J ;

Pelemans, H ;

Heijtink, R ;

DeClercq, E ;

McGuigan, C .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1996, 225 (02) :363-369

[3] Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation [J].

Bartholomew, MM ;

Jansen, RW ;

Jeffers, LJ ;

Reddy, KR ;

Johnson, LC ;

Bunzendahl, H ;

Condreay, LD ;

Tzakis, AG ;

Schiff, ER ;

Brown, NA .

LANCET, 1997, 349 (9044) :20-22

[4] Effects of lamivudine on replication of hepatitis B virus in HIV-infected men [J].

Benhamou, Y ;

Katlama, C ;

Lunel, F ;

Coutellier, A ;

Dohin, E ;

Hamm, N ;

Tubiana, R ;

Herson, S ;

Poynard, T ;

Opolon, P .

ANNALS OF INTERNAL MEDICINE, 1996, 125 (09) :705-+

[5] EFFICACY OF LAMIVUDINE ON REPLICATION OF HEPATITIS-B VIRUS IN HIV-INFECTED PATIENTS [J].

BENHAMOU, Y ;

DOHIN, E ;

LUNELFABIANI, F ;

POYNARD, T ;

HURAUX, JM ;

KATLAMA, C ;

OPOLON, P ;

GENTILINI, M .

LANCET, 1995, 345 (8946) :396-397

[6] Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study [J].

Benhamou, Y ;

Bochet, M ;

Thibault, V ;

Calvez, V ;

Fievet, MH ;

Vig, P ;

Gibbs, CS ;

Brosgart, C ;

Fry, J ;

Namini, H ;

Katiama, C ;

Poynard, T .

LANCET, 2001, 358 (9283) :718-723

[7] Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients [J].

Benhamou, Y ;

Bochet, M ;

Thibault, V ;

Di Martino, V ;

Caumes, E ;

Bricaire, F ;

Opolon, P ;

Katlama, C ;

Poynard, T .

HEPATOLOGY, 1999, 30 (05) :1302-1306

[8] Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine [J].

Bessesen, M ;

Ives, D ;

Condreay, L ;

Lawrence, S ;

Sherman, KE .

CLINICAL INFECTIOUS DISEASES, 1999, 28 (05) :1032-1035

[9]

BOCHET M, 2002, 9 C RETR VIR OPP INF

[10] THE INFLUENCE OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION ON THE DEVELOPMENT OF THE HEPATITIS-B VIRUS CARRIER STATE [J].

BODSWORTH, NJ ;

COOPER, DA ;

DONOVAN, B .

JOURNAL OF INFECTIOUS DISEASES, 1991, 163 (05) :1138-1140

← 1 2 3 4 5 6 7 →